Pharmaceutical

Tempest hits funding block for Phase III liver cancer drug-in-waiting

Tempest Therapeutics is eyeing a strategic partner to continue amezalpat’s development amid ‘unavailable capital markets.’

Apr 12, 2025 - 06:00
Tempest hits funding block for Phase III liver cancer drug-in-waiting
Tempest Therapeutics is eyeing a strategic partner to continue amezalpat’s development amid ‘unavailable capital markets.’
Read the original article

Tags:

Previous Article

Cingulate secures $3m to advance once-daily anxiety treatment

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Senate panel passes a suite of drug pricing bills — but fails to advance one major PBM reform

STAT+: Senate panel passes a suite of drug pricing bill...

May 11, 2023

Evotec partners with Crohn’s & Colitis Foundation for IBD therapies

Evotec partners with Crohn’s & Colitis Foundation for I...

Jan 11, 2024

Opinion: The CDC’s new, relaxed Covid isolation guidance makes perfect sense

Opinion: The CDC’s new, relaxed Covid isolation guidanc...

Mar 6, 2024